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ABSTRACT
TUG-891 [3-(4-((4-fluoro-49-methyl-[1,19-biphenyl]-2-yl)methoxy)phe-
nyl)propanoic acid] was recently described as a potent and
selective agonist for the long chain free fatty acid (LCFA) receptor
4 (FFA4; previously G protein–coupled receptor 120, or GPR120).
Herein, we have used TUG-891 to further define the function of
FFA4 and used this compound in proof of principle studies
to indicate the therapeutic potential of this receptor. TUG-891
displayed similar signaling properties to the LCFA a-linolenic acid
at human FFA4 across various assay end points, including
stimulation of Ca21 mobilization, b-arrestin-1 and b-arrestin-2
recruitment, and extracellular signal-regulated kinase phosphor-
ylation. Activation of human FFA4 by TUG-891 also resulted in
rapid phosphorylation and internalization of the receptor. While
these latter events were associated with desensitization of the
FFA4 signaling response, removal of TUG-891 allowed both rapid
recycling of FFA4 back to the cell surface and resensitization of
the FFA4 Ca21 signaling response. TUG-891 was also a potent
agonist of mouse FFA4, but it showed only limited selectivity
over mouse FFA1, complicating its use in vivo in this species.
Pharmacologic dissection of responses to TUG-891 in model
murine cell systems indicated that activation of FFA4 was able to
mimic many potentially beneficial therapeutic properties pre-
viously reported for LCFAs, including stimulating glucagon-like
peptide-1 secretion from enteroendocrine cells, enhancing
glucose uptake in 3T3-L1 adipocytes, and inhibiting release of
proinflammatory mediators from RAW264.7 macrophages, which
suggests promise for FFA4 as a therapeutic target for type 2
diabetes and obesity. Together, these results demonstrate both
potential but also significant challenges that still need to be
overcome to therapeutically target FFA4.
Introduction
Fatty acids are important biologic molecules that serve both
as a source of energy and as signaling molecules regulating
metabolic and inflammatory processes. In the past, fatty
acids were believed to produce their biologic effects through
interacting with intracellular targets including, for example,
the family of peroxisome proliferator-activated receptors.
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ABBREVIATIONS: aLA, a-linolenic acid; BRET, bioluminescence resonance energy transfer; BSA, bovine serum albumin; DHA, docosahexaenoic
acid; DMEM, Dulbecco’s modified Eagle’s medium; EGF, epidermal growth factor; ELISA, enzyme-linked immunosorbent assay; ERK, extracellular
signal-regulated kinase; eYFP, enhanced yellow fluorescent protein; FBS, fetal bovine serum; FFA, free fatty acid; GLP-1, glucagon-like peptide-1;
GPCR, G protein–coupled receptor; GW1100, 4-[5-[(2-ethoxy-5-pyrimidinyl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-4-oxo-1(4H)-pyrimidinyl]-benzoic acid,
ethyl ester; GW9508, 4-[[(3-phenoxyphenyl)methyl]amino]benzenepropanoic acid; HA, hemagglutinin; HBSS, Hanks’ balanced salt solution; HEK293T,
human embryonic kidney 293T cells; Iressa, N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; KR-62436, 6-[2-
[[2-(3-cyano-3,4-dihydropyrazol-2-yl)-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile; LCFA, long chain fatty acid; LPS, lipopolysaccharide; NCG21, 4-
{4-[2-(phenyl-2-pyridinylamino)ethoxy]phenyl}butyric acid; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; RT-PCR, reverse-transcription
polymerase chain reaction; siRNA, small interfering RNA; TMD, transmembrane domain; TNF, tumor necrosis factor; TUG-891, 3-(4-((4-fluoro-49-methyl-[1,19-
biphenyl]-2-yl)methoxy)phenyl)propanoic acid; TUG-905, 3-(2-fluoro-4-(((29-methyl-49-(3-(methylsulfonyl)propoxy)-[1,19-biphenyl]-3-yl)methyl)amino)phe-
nyl)propanoic acid; YM-254890, (1R)-1-{(3S,6S,9S,12S,18R,21S,22R)-21-acetamido-18-benzyl-3-[(1R)-1-methoxyethyl]-4,9,10,12,16,22-hexamethyl-
15-methylene-2,5,8,11,14,17,20-heptaoxo-1,19-dioxa-4,7,10,13,16-pentaazacyclodocosan-6-yl}-2-methylpropyl (2S,3R)-2-acetamido-3-hydroxy-4-
methylpentanoate.
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However, in recent years it has become clear that fatty acids
also serve as agonists for a group of cell surface G protein–
coupled receptors (GPCRs). These include three closely related
receptors designated as a free fatty acid (FFA) receptor family:
FFA1 (previously G protein–coupled receptor 40, or GPR40),
FFA2 (previously GPR43) and FFA3 (previously GPR41)
(Stoddart et al., 2008a); as well as two additional, structurally
more distantly related GPCRs: GPR120 (Hirasawa et al., 2005)
and GPR84 (Wang et al., 2006). Although the relevance of fatty
acid ligands on GPR84 remains uncertain, the ability of long
chain fatty acids (LCFAs) to activate GPR120 is now well
established (Hirasawa et al., 2005; Oh et al., 2010). As a result,
despite limited homology with the other family members,
GPR120 has recently been added to the FFA family of receptors
and is now designated FFA4.
Since the deorphanization of the FFA receptor familymembers,
these receptors have been implicated in many of the biologic
effects of fatty acids on both metabolic and inflammatory pro-
cesses; as a consequence, great interest has accrued in devel-
oping novel pharmacologic reagents to assess the therapeutic
potential of these receptors (Holliday et al., 2011; Ulven, 2012;
Hudson et al., 2013b). To date, FFA1 has received the greatest
attention based on clear validation as a target for the treatment
of type 2 diabetes because of its ability to enhance glucose-
stimulated insulin secretion (Itoh et al., 2003); at least one FFA1
agonist has progressed through phase II clinical trials for this
prospective end point (Burant et al., 2012; Kaku et al., 2013).
However, interest in FFA4 has also been steadily growing, again
for the treatment of type 2 diabetes and/or obesity. Early studies
have indicated that FFA4 is expressed highly in enteroendocrine
cells and suggested that it may mediate LCFA-stimulated
release of glucagon-like peptide-1 (GLP-1) from these cells
(Hirasawa et al., 2005). Furthermore, FFA4 expressed by
adipocytes is reported to enhance glucose uptake, and in
macrophages the activation of FFA4 appears to be anti-
inflammatory, hence promoting improved insulin sensitiv-
ity (Oh et al., 2010). Moreover, recent data suggest FFA4 is
expressed in the pancreas and that it can protect pancreatic
islets from palmitate-induced apoptosis (Taneera et al.,
2012). Taken together, these findings suggest that FFA4 may
play an important role in both metabolic and inflammatory
processes associated with the development of type 2 diabetes
and that agonism of this receptor could represent a promis-
ing and novel therapeutic approach.
Further support for FFA4 as a therapeutic target has come
recently from genetic studies in both mice and humans,
showing that mice genetically lacking the receptor or humans
possessing an FFA4 polymorphism with reduced signaling
activity are both prone to obesity (Ichimura et al., 2012).
However, despite all of these promising and tantalizing
findings, a lack of synthetic ligands with high potency and
selectivity for FFA4 has meant that many of the previous
studies have been indirect or have relied on the use of fatty
acids only as ligands. This has greatly limited proof-of-
principle studies to validate FFA4 more fully as a therapeutic
target. In particular, identifying ligands with suitable selectivity
for FFA4 over the other LCFA receptor FFA1 has been
challenging (Hudson et al., 2011). Early FFA4 “selective”
compounds reported in the academic literature displayed
only poor potency and very limited selectivity over FFA1
(Suzuki et al., 2008; Hara et al., 2009a). However, we have
recently reported a highly potent and selective agonist of
FFA4, with TUG-891 [3-(4-((4-fluoro-49-methyl-[1,19-biphenyl]-
2-yl)methoxy)phenyl)propanoic acid] (Shimpukade et al., 2012)
potentially offering a suitable tool compound with which to
selectively probe FFA4 function.
In this study, we examine the in vitro function of TUG-891
in cells transfected to express species orthologs of the receptor.
We demonstrate that this ligand possesses similar signaling
properties to the endogenous fatty acids at FFA4 but with
significantly greater potency and selectivity. We establish that
this ligand can be used to examine FFA4 function in cells
endogenously expressing the receptor and that it produces
many of the beneficial properties previously associated with
activation of the receptor, including stimulating GLP-1 release,
enhancing glucose uptake, and inhibiting proinflammatory
cytokine secretion. However, as noted in early studies (Hirasawa
et al., 2005; Fukunaga et al., 2006; Watson et al., 2012), agonist
treatment results in rapid and extensive removal of FFA4 from
the surface of cells, andwe now also demonstrate desensitization
of functional responses. Although this may pose challenges for
the therapeutic development of FFA4 agonists, we also observe
that functional responses are rapidly reestablished after re-
moval of TUG-891, suggesting that this issuemay not ultimately
preclude therapeutic agonist development at FFA4.
Materials and Methods
TUG-891 was synthesized as described previously elsewhere
(Shimpukade et al., 2012). NCG21 (4-{4-[2-(phenyl-2-pyridinylami-
no)ethoxy]phenyl}butyric acid) was synthesized based on the protocol
described by Suzuki et al. (2008). TUG-905 [3-(2-fluoro-4-(((29-methyl-
49-(3-(methylsulfonyl)propoxy)-[1,19-biphenyl]-3-yl)methyl)amino)phe-
nyl)propanoic acid] was synthesized as described by Christiansen et al.
(2012). GW9508 (4-[[(3-phenoxyphenyl)methyl]amino]benzenepropanoic
acid)waspurchased fromSigma-Aldrich (Poole,UK), andGW1100 (4-[5-[(2-
ethoxy-5-pyrimidinyl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-4-
oxo-1(4H)-pyrimidinyl]-benzoic acid, ethyl ester) was obtained from
Cayman Chemical (Ann Arbor, MI). YM-254890 [(1R)-1-{(3S,6S,9S,
12S,18R,21S,22R)-21-acetamido-18-benzyl-3-[(1R)-1-methoxyethyl]-
4,9,10,12,16,22-hexamethyl-15-methylene-2,5,8,11,14,17,20-heptaoxo-
1,19-dioxa-4,7,10,13,16-pentaazacyclodocosan-6-yl}-2-methylpropyl
(2S,3R)-2-acetamido-3-hydroxy-4-methylpentanoate] (Takasaki et al.,
2004) was the kind gift of Astellas Pharma, Inc. (Osaka, Japan) and
Iressa [N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-
ylpropoxy)quinazolin-4-amine] was obtained from Tocris Biosciences
(Bristol, UK). Tissue culture reagents were obtained from Life Tech-
nologies (Paisley, UK). Molecular biology enzymes and reagents were
obtained from Promega (Southampton, UK). The radiochemical [3H]de-
oxyglucose was obtained from PerkinElmer Life and Analytical Sciences
(Beaconsfield, Buckinghamshire, UK). All other experimental re-
agents were purchased from Sigma-Aldrich.
Plasmids and Mutagenesis. All plasmids used encoded human
or mouse FFA1 or FFA4 (short isoform) receptors with enhanced yellow
fluorescent protein (eYFP) fused to their C terminus and incorporating an
N-terminal FLAG epitope tag (FFA4 constructs only) in the pcDNA5 FRT/
TO expression vector, as described previously elsewhere (Smith et al., 2009;
Christiansen et al., 2012; Shimpukade et al., 2012). To generate the hFFA4
construct containing a C-terminal hemagglutinin (HA) epitope tag, the
FFA4 sequence was amplified by polymerase chain reaction (PCR) using
the primers F-TTTTAAGCTTGCCACCATGTCCCCTGAATGCGC and
R-TTTTGGATCCTTAAGCGTAATCTGGAACATCGTATGGGTAGCCA
GAAATAATCGACAAGTCA, which incorporate the HA tag se-
quence followed by a stop codon immediately after the last residue
of FFA4. The individual point mutations R99Q and R178Q were
introduced into theFLAG-hFFA4-eYFPplasmid using theQuikChange
method (Stratagene; Agilent Technologies, Santa Clara, CA).
The Therapeutic Potential of FFA4 711
 at A
SPET Journals on February 5, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
Cell Culture, Transfection, and Stable Cell Lines. In experi-
ments using transient heterologous expression, we employed human
embryonic kidney (HEK)293T cells. These were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS) at 37°C and 5% CO2.
Transfections were performed with polyethylenimine, and experi-
ments were conducted 48 hours after transfection. In experiments
using stable heterologous expression, the Flp-In T-REx system (Life
Technologies) was used to generate 293 cells with doxycycline-inducible
expression of the receptor of interest. All experiments performed using
these cells were conducted after 24 hours of treatment with 100 ng/ml
doxycycline to induce receptor expression. Receptor phosphorylation
experiments were performed on Chinese hamster ovary Flp-In cells
stably transfected with FFA4-HA and cultured in Ham’s F-12 1
Glutamax (Life Technologies) containing 10% heat-inactivated FBS,
50units/ml penicillin, 50mg/ml streptomycin, and 400mg/ml hygromycin b.
Cells were maintained at 37°C with 5% CO2.
In experiments where small interfering RNA (siRNA) was used to
knockdown b-arrestin-2 expression, FFA4 Flp-In T-REx were seeded
at 25,000 cells/well in 96-well plates 24 hours before transfecting
with a pool of four either nontargeting or b-arrestin-2–specific siRNA
oligonucleotides (Thermo Fisher Scientific, Waltham, MA) using the
lipofectamine 2000 transfection reagent. Cells were transfected with
a second round of siRNA 24 hours later, treated with doxycycline to
induce FFA4 expression (100 ng/ml), and incubated 24 hours before
use in experiments. Successful knockdown of b-arrestin-2 mRNA was
confirmed by reverse-transcription polymerase chain reaction (RT-
PCR) using forward: GAGCCCTAACTGCAAGCTCA and reverse:
AGTGTGACGGAGCATGGAAG primers.
For experiments using differentiated mouse adipocytes, 3T3-L1
fibroblasts were maintained and differentiated as described pre-
viously elsewhere (Hudson et al., 2013a). Murine STC-1 and GLUTag
enteroendocrine cells were maintained in DMEM supplemented with
10% heat inactivated FBS and maintained at 37°C and 5% CO2. For
experiments, cells were plated in 24-well plates and cultured for
at least 24 hours before initiating GLP-1 secretion experiments.
RAW264.7 mouse macrophages were cultured in DMEM supplemented
with 10% heat inactivated FBS and maintained at 37°C and 5% CO2
and plated in 96-well plates for tumor necrosis factor (TNF) secretion
experiments. HT-29 human adenocarcinoma cells were maintained in
McCoy’s 5A medium supplemented with 10% heat-inactivated FBS and
maintained at 37°C and 5% CO2. FFA4 expression in HT-29 cells was
confirmed by RT-PCR using the primers F-59-CGCGACCAGGAAATTTC-
GATT-39 and R-59-GTGAGCCTCTTCCTTGATGC-39, which spanned the
third intracellular loop region allowing for the separate detection of the
short (167-bp product) and long (215-bp product) isoforms of human FFA4.
Signaling Assays To Assess FFA4 Function. b-Arrestin-1 and -2
recruitment to FFA1 or FFA4 was assessed in transiently transfected
HEK293T cells after 5 minutes of ligand treatment using the previ-
ously described bioluminescence resonance energy transfer protocol
(Shimpukade et al., 2012). Ca21 mobilization experiments were per-
formed using Flp-In T-REx stable-inducible cell lines or HT-29 cells
according to the previously described protocol (Hudson et al., 2012a). In
these experiments, intracellular Ca21 was monitored for 90 seconds
after ligand treatment, and the measured response was taken as the
peak signal over this time course. Extracellular signal-regulated
kinase 1/2 (ERK) phosphorylation was examined in Flp-In T-REx cell
lines, or in HT-29 cells after 5 minutes of ligand treatment (unless
otherwise indicated) using a protocol previously described elsewhere
(Hudson et al., 2012a).
Visualization of FFA4 Internalization. Human FFA4-eYFP
Flp-In T-REx cells were cultured on poly-D-lysine coated glass
coverslips and cultured for 24 hours before treatment with doxycy-
cline (100 ng/ml) to induce receptor expression. Live cells were then
imaged using a Zeiss VivaTome spinning disk confocal microscopy
system (Karl Zeiss, Oberkochen, Germany). Images were taken before
the addition of ligand, and every 5 minutes after ligand addition for
a total of 45 minutes.
High Content Imaging Quantitative Internalization Assay
and Cell Surface Enzyme-Linked Immunosorbent Assay. Hu-
man FFA4-eYFP Flp-In T-REx cells were plated 75,000 cells per well
in black with clear bottom 96-well plates. Cells were allowed to adhere
for 3 to 6 hours before the addition of doxycycline (100 ng/ml) to induce
receptor expression. After an overnight incubation, culture medium
was replaced with serum-free DMEM containing the ligand to be
assayed. Cells were incubated at 37°C for the times indicated before
fixation with 4% paraformaldehyde. After washing with phosphate-
buffered saline (PBS), cells were stained for 30 minutes with Hoechst
33342, washed again and plates imaged using a Cellomics Arrayscan
II high content plate imager (Thermo Fisher Scientific). Images were
processed to identify internalized eYFP, which was then normalized
to cell number based on nuclei identified by Hoechst staining to obtain
a quantitative measure of hFFA4-eYFP internalization.
After imaging the plate, if FFA4 cell surface expression was also to
be measured, the fixed cells were first incubated in PBS containing
5% bovine serum albumin (BSA) to block nonspecific binding sites
(30 minutes at room temperature), followed by incubation with an
anti-FLAG monoclonal primary antibody (30 minutes at room temper-
ature), and finally with an anti-mouse horseradish peroxidase conjugated
secondary antibody (30 minutes at room temperature). Cells were
washed 3 times with PBS beforemeasuringHoechst fluorescence using
a PolarStar Omega plate reader (BMG Labtech, Offenburg, Germany).
After washing a final time with PBS, and incubating with 3,39,5,59-
tetramethylbenzidine horseradish peroxidase substrate in the dark at
room temperature, the absorbance at 620nmwasmeasured on aPolarStar
Omega plate reader. To calculate surface expression, the 620 nm
absorbance corrected for cell number based on Hoechst fluorescence
was expressed as a percentage of the control wild-type FFA4 signal.
FFA4 Phosphorylation and Phosphopeptide Mapping. Chi-
nese hamster ovary cells which stably and constitutively expressed
the C-terminal HA epitope tagged FFA4 were generated. Cells were
plated in 6 wells at 200,000 cells per well 24 hours before experimen-
tation. For phosphorylation experiments, cells were washed 3 times with
Krebs/HEPES buffer without phosphate [118 mM NaCl, 1.3 mM CaCl2,
4.3 mM KCl, 1.17 MgSO4, 4.17 mM NaHCO3, 11.7 mM glucose, 10 mM
HEPES (pH 7.4)] and incubated in this buffer containing 100 mCi/ml
32P orthophosphate for 1 hour at 37°C. Cells were stimulated for
5minutes with test compounds andwere immediately lysed by addition
of buffer containing 20mMTris pH 7.4, 150mMNaCl, 3mMEDTA, 1%
NP-40, 0.5% Na deoxycholate. FFA4 was immunoprecipitated from the
cleared lysates using anti-HA Affinity Matrix (Roche Applied Science,
Penzberg, Germany). The washed immunoprecipitates were separated by
SDS-PAGE on 10% gels which were dried, and radioactive bands were
revealed using autoradiography film. The films were scanned and bands
quantified using AlphaImager software (Alpha Innotech, SanLeandro, CA).
For phosphopeptide mapping experiments, 32P-labeled FFA4 immu-
noprecipitates were transferred to polyvinylidene difluoride, and the
band corresponding to FFA4 was excised and blocked in 0.5%
polyvinylpyrrolidone K30 in 0.6% acetic acid at 37°C for 30 minutes.
Tryptic peptides were generated by incubating themembranewith 1mg
sequencing grade trypsin (Promega) overnight. The resulting superna-
tant was dried and resuspended in loading buffer [88% formic acid/
acetic acid/water, 25:78:897 (v/v/v), pH 1.9].
Peptides were applied to a 20  20 cm cellulose thin-layer
chromatography plate and separated by electrophoresis for 30 minutes
at 2000 V followed by ascending chromatography in isobutyric acid
chromatography buffer [isobutyric acid/n-butanol/pyridine:acetic acid/
water, 1250:38:96:58:558 (v/v/v/v/v)]. The dried plate was exposed to
a storage phosphor screen for 10 days after which radioactivity was
visualized using a Storm 820 Imager (Amersham Biosciences,
Piscataway, NJ).
Single-Cell Calcium Imaging. Human FFA4-eYFP Flp-In
T-REx cells were cultured on poly-D-lysine coated glass coverslips
for 24 hours before the addition of doxycycline (100 ng/ml) to induce
receptor expression. Single-cell Ca21measurements were then performed
as described previously elsewhere (Stoddart et al., 2008b).
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GLP-1 Secretion from Enteroendocrine Cell Lines. STC-1 or
GLUTag cells were washed with Hanks’ balanced salt solution
(HBSS) supplemented with 20 mM HEPES before the addition of the
test compound in HBSS/HEPES containing the dipeptidyl peptidase-4
inhibitor KR-62436 (6-[2-[[2-(3-cyano-3,4-dihydropyrazol-2-yl)-2-oxoeth-
yl]amino]ethylamino]pyridine-3-carbonitrile; 2.5 mM) to prevent peptidase
activity and the hydrolysis of GLP-1. Cells were incubated at 37°C for
1 hour before the cell supernatants were collected inmicrocentrifuge tubes.
Supernatants were then centrifuged to eliminate any cellular debris and
assayed for GLP-1 concentration using an active GLP-1 enzyme-linked
immunosorbent assay (ELISA) kit (Millipore, Billerica, MA).
[3H]Deoxyglucose Uptake Assay in Differentiated 3T3-L1
Adipocytes. On the day of the assay, differentiated 3T3-L1 adipocytes
were washed once then incubated with serum-free DMEM for 2 hours
at 37°C. The cells were transferred to a hot plate maintained at 37°C
and then washed 3 times with Krebs-Ringer-phosphate buffer (128mM
NaCl, 1.25 mM CaCl2, 4.7 mM KCl, 5.0 mM NaH2PO4, 1.25 mM
MgSO4). Cells were then incubated for 30 minutes in KRP containing
either the ligand to be assayed or insulin before the addition of a
[3H]deoxyglucose/deoxyglucose solution, yielding final assay concen-
trations of 1 mCi of [3H]deoxyglucose and 50 mM deoxyglucose. After
incubating 5 minutes to allow for [3H]deoxyglucose uptake, the Krebs-
Ringer-phosphate buffer was removed quickly by inverting before the
plates were submerged sequentially 3 times in ice-cold PBS to stop the
reaction and wash the cells. The plates were then allowed to dry for at
least 30 minutes before the cells were solubilized overnight with 1%
Triton X-100. The solubilized material was then collected, and the
[3H] levels assessed by liquid scintillation spectrometry.
TNF Secretion from RAW264.7 Macrophages. RAW264.7
macrophages were plated 25,000 cells per well in 96-well plates and
cultured overnight. Medium was removed and replaced with fresh
serum-free medium supplemented with 0.01% BSA, and containing
the compound to be tested. After a 1-hour incubation, lipopolysaccha-
ride (LPS) was added (100 ng/ml) to stimulate TNF release. Cells were
maintained for 6 hours at 37°C before supernatants were collected
and assayed for TNF in low-volumewhite 384well plates using amouse
TNF AlphaLISA assay kit (PerkinElmer, Waltham, MA).
Data Analysis and Curve Fitting. Data presented represent
mean6 S.E. of at least three independent experiments. Data analysis
and curve fitting was performed using the Graphpad Prism software
package v5.0b (GraphPad Software, La Jolla, CA). Concentration-
response data were plotted on a log axis, where the untreated vehicle
control condition was plotted at one log unit lower than the lowest test
concentration of ligand and fitted to three-parameter sigmoidal
concentration-response curves. Statistical analysis was performed
using standard t tests or one-way analysis of variance followed by
Tukey’s post-hoc tests, as appropriate.
Results
TUG-891 Is a Potent Agonist of FFA4. Postactivation
assays were established to examine the ability of TUG-891
and various other ligands to activate FFA4. Initially, we
compared the actions of TUG-891 (Fig. 1A) with key ligands
with previously reported agonist activity at FFA4. These
included the endogenous fatty acid agonist a-linolenic acid
(aLA) (Fig. 1A); the FFA1 selective agonist GW9508 (Fig. 1A)
(Briscoe et al., 2006), which has been used in the absence of
other ligands to study FFA4 function; and NCG21 (Fig. 1A),
the most selective synthetic FFA4 agonist previously de-
scribed in the academic literature (Suzuki et al., 2008). FFA4
has been shown to couple to Gaq/11-initiated signal trans-
duction pathways, and, as such, we first assessed the activity
of these four compounds in Ca21mobilization assays employ-
ing Flp-In T-REx 293 cells that had been engineered to
express human FFA4 (hFFA4) only upon treatment with the
antibiotic doxycycline. All four ligands produced concentration-
dependent increases in intracellular Ca21, with TUG-891 being
the most potent—approximately 7-fold more potent than GW9508,
and 50-fold more potent than aLA and NCG21 (Fig. 1B; Table 1).
These responses to each ligand reflected activation of FFA4, as
no responses were observed in cells that had not been treated
with doxycycline to induce expression of hFFA4 (data not
shown).
In addition to promoting signaling via the Gq/11 G proteins,
FFA4 has also been reported to couple to G protein–independent,
b-arrestin-2–mediated pathways (Oh et al., 2010; Shimpukade
et al., 2012). Sowe next examined the potency of the same ligands
in a b-arrestin-2 recruitment assay based on bioluminescence
resonance energy transfer (BRET) using HEK293T cells tran-
siently cotransfected with an eYFP-tagged form of hFFA4 and
aRenilla luciferase-tagged form of b-arrestin-2 (Fig. 1C). All four
compounds again produced concentration-dependent responses
with a rank-order of potency similar to that observed in the Ca21
assays. TUG-891 was the most potent, and was approximately
10-fold more potent than GW9508, 35-fold more than NCG21,
and 80-fold more potent than aLA (Table 1). We also established
a similar BRET assay to examine b-arrestin-1 recruitment to
FFA4. Each ligand was able to recruit b-arrestin-1 with the
same rank-order, although with slightly reduced potency, com-
pared with b-arrestin-2 recruitment (Table 1).
FFA4 activation has also been linked to increased phos-
phorylation of ERK1/2 (Suzuki et al., 2008). Activation of ERK
can be induced by either G protein–dependent or –indepen-
dent pathways (Shenoy et al., 2006). In this assay, again using
hFFA4-inducible Flp-In T-REx 293 cells, only TUG-891 and
GW9508 produced activation in a clear, concentration-dependent
manner, and aLA and NCG21 only increased ERK phosphoryla-
tion at the highest concentrations that could be employed (Fig.
1D). Interestingly, although the rank-order of potency observed
in the other assays of TUG-891 . GW9508 . NCG21  aLA
remained intact in the ERK assay, the potency of each
compound was statistically significantly reduced (P , 0.001)
in this assay compared with the values obtained from either
Ca21mobilization or b-arrestin-2 interaction studies (Table 1).
Construction of “bias plots” (Gregory et al., 2010) that compared
responses to equivalent concentrations of ligand between each
of the three assays (Fig. 1, E–G) clearly demonstrated an
inherent bias in FFA4 signaling toward Ca21 and b-arrestin-2
recruitment overERKphosphorylation.However, as the bias-plot
profiles were similar for all four ligands in each assay comparison,
these data suggest that each ligand is likely to activate the
receptor in a similar manner.
FFA4 Stimulates ERK Phosphorylation Primarily
through Gq/11. Because GPCRs are known to stimulate ERK
phosphorylation through a number of different pathways, we
explored the mechanism(s) allowing FFA4-mediated ERK
activation. Time course studies (Fig. 2A) indicated that aLA
and TUG-891 produced similar kinetic pERK response profiles.
An initial peak response was observed within 2.5 minutes,
followed by a rapid decrease in pERK until 10 minutes of
ligand treatment when the pERK levels plateaued. This was
followed by a gradual decline in pERK up to 60 minutes of
ligand treatment, when levels had returned close to basal.
By contrast, treatment with 10% (v/v) FBS resulted in a
slower pERK response, reaching a peak at 5 minutes that
decreased much more rapidly, returning to basal levels
within 10 minutes.
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We next examined whether the pERK response was Gq/11-
mediated and/or involved transactivation of the epidermal growth
factor (EGF) receptor, as shown for FFA4 in Caco-2 adenocarci-
noma cells (Mobraten et al., 2013). TheGq/11 inhibitor YM-254890
statistically significantly inhibited but did not eliminate the
5-minute response to either aLA (P , 0.05; 52% reduction)
or TUG-891 (P , 0.001; 65% reduction) (Fig. 2B). In contrast,
YM-254890 did not inhibit the 5-minute response produced by
FBS (P . 0.05) (Fig. 2B). The EGF-receptor inhibitor Iressa
had no effect on the 5-minute response to any of the ligands.
We also assessed any effects of YM-254890 or Iressa on the
pERK plateau observed after 15 minutes of treatment with
either aLA or TUG-891 (Fig. 2C). At this time point,
YM-254890 also statistically significantly reduced the
pERK response to both aLA and TUG-891 (P , 0.001),
reductions of 60% 6 9% and 70% 6 7%, respectively. Now,
however, Iressa also partially inhibited the pERK responses by
33% 6 7% to aLA (P , 0.001) and by 31% 6 12% to TUG-891
(P, 0.05). Moreover, combined treatment with both YM-254890
and Iressa entirely eliminated pERK activation by both ligands
at 15 minutes. To confirm that Iressa and YM-254890 were
able to effectively block EGF receptor- and Gq/11-mediated
signaling respectively at the concentrations used, we demon-
strated that Iressa completely blocked EGF-mediated ERK
phosphorylation (Fig. 2D) and that YM-254890 completely
eliminated the TUG-891–mediated elevation of [Ca21] in these
cells (Fig. 2E).
Because neither YM-254890 nor Iressa were able to fully
block FFA4-mediated ERK phosphorylation at the peak time
point, this suggests other pathways are involved. Thus, we
also examined whether a portion of this FFA4 pERK response
might be mediated by b-arrestin-2. We used siRNA to knock
down expression of b-arrestin-2 in the FFA4-eYFP Flp-In
T-REx 293 cell line and assessed pERK induction by aLA,
Fig. 1. TUG-891 is a potent agonist of FFA4. (A) Chemical structures of the ligands: aLA, GW9508, NCG21, and TUG-891. Concentration-response data
for each agonist at hFFA4 are shown in (B) Ca2+ mobilization, (C) b-arrestin-2 recruitment, and (D) ERK phosphorylation assays. Bias plots are also
shown comparing responses to equal concentrations of each ligand between (E) b-arrestin-2 recruitment and ERK phosphorylation, (F) b-arrestin-2
recruitment and Ca2+ mobilization, or (G) ERK phosphorylation and Ca2+ mobilization assays. On these plots, a theoretical relationship for a complete
lack of bias between pathways is shown in the dashed line.
TABLE 1
pEC50 potency values of agonists at hFFA4 in various functional assays
Assay aLA GW9508 NCG21 TUG-891
Ca2+ 5.25 6 0.10 6.07 6 0.08 5.21 6 0.11 6.93 6 0.07
b-Arrestin-2 5.29 6 0.05 6.04 6 0.04 5.64 6 0.03 7.19 6 0.07
b-Arrestin-1 4.86 6 0.05 5.64 6 0.04 ND 6.83 6 0.06
pERK 4.08 6 0.14 5.06 6 0.25 ,4.5 5.83 6 0.12
Internalization 4.76 6 0.11 5.25 6 0.10 5.51 6 0.18 7.29 6 0.12
ND, not determined.
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TUG-891, and FBS after 5 minutes (Fig. 2F). In each case, the
pERK response was unaffected, despite the fact that the
siRNA did greatly reduce b-arrestin-2 mRNA levels. To
confirm that we had achieved functional knockdown of
b-arrestin-2, we observed TUG-891–mediated internalization
of FFA4-eYFP in control or b-arrestin-2 siRNA transfected
cells by fluorescent microscopy (Fig. 2G). We observed an
apparent reduction in FFA4-internalization in b-arrestin-2
siRNA transfected cells, and quantitative measure of this
indicated that the siRNA resulted in a 70%6 9% reduction in
TUG-891–mediated internalization of FFA4 (Fig. 2H). These
results indicate a lack of involvement of b-arrestin-2 in FFA4-
mediated ERK phosphorylation in these cells. Instead, FFA4
rapidly activates ERK primarily through Gq/11, whereas the
more sustained pERK response involves a combination of Gq/11
and EGF transactivation pathways.
TUG-891 Stimulates Rapid Internalization, Phos-
phorylation, and Desensitization of FFA4. Like many
GPCRs, after ligand activation, FFA4 can be internalized
away from the plasma membrane (Hirasawa et al., 2005;
Watson et al., 2012). In the hFFA4 Flp-In T-REx 293 cell line,
internalization of hFFA4-eYFP was assessed by confocal
microscopy. Before ligand treatment, hFFA4-eYFPwas located
primarily at the cell surface, but within 10 minutes of the
addition of 100 mM aLA, an increase in intracellular hFFA4-
eYFP expression was observed, with a punctate distribution
(Fig. 3A). The amount of internalized hFFA4-eYFP increased
over time, and within the 45-minute incubation period employed
there was very little hFFA4-eYFP that could be observed at the
cell surface. We found that 10 mM TUG-891 produced a similar
pattern of internalization (Fig. 3B).
To quantify these effects, we employed a high content imaging
assay that measures the intensity of eYFP fluorescence within
internal cellular compartments, an approach that has been
used previously to quantitatively assess FFA4 internalization
(Fukunaga et al., 2006; Watson et al., 2012). This assay demon-
strated that the amount of internalized receptor increased in
a quasi-linear fashion for both ligands and with similar
kinetics, reaching a maximum level within 40 minutes (Fig.
3C). Interestingly, although the potency of TUG-891 in this
assay was similar to that of the BRET b-arrestin-2 and Ca21
assays (Table 1), the rank-order of potency for the four
ligands was distinct: TUG-891.NCG21.GW9508. aLA
(Fig. 3D).
In addition to being internalized away from the cell surface,
many GPCRs become phosphorylated rapidly after ligand
activation both to promote interactions with b-arrestins and
as a means to induce desensitization. Previous studies have
demonstrated phosphorylation of FFA4 in response to fatty
acid ligands (Burns and Moniri, 2010). We confirmed that as
well as aLA, TUG-891 was able to promote phosphorylation of
hFFA4 (Fig. 3, E and F). Furthermore, aLA and TUG-891
appeared to stimulate phosphorylation at the same sites, as
indicated by the fact that the patterns of phosphopeptides
Fig. 2. FFA4 activates ERK phosphorylation primarily through Gq/11-mediated pathways. (A) Time course pERK analysis was performed in hFFA4-
eYFP Flp-In T-REx 293 cells in response to aLA (300 mM; black circles), TUG-891 (10 mM; dark gray squares), or FBS (10%; light gray triangles). (B) The
5-minute pERK responses to aLA (300 mM; black), TUG-891 (10 mM; dark gray), and FBS (10%; light gray) are shown from control, YM-254890 (YM;
100 nM), or Iressa (1 mM) pretreated cells. *P, 0.05; ***P, 0.001 compared with control for the same ligand. (C) Similar experiments after 15-minute
treatment with either aLA (300 mM; black) or TUG-891 (10 mM; dark gray). In this graph, the dashed line indicates the basal pERK level. *P , 0.05;
***P, 0.001 compared with control for the same ligand. (D) Effect of Iressa (10 mM) pretreatment on the EGF receptor pERK response. ***P, 0.001. (E)
The Ca2+ response to TUG-891 without or with YM (100 nM) pretreatment. (F) pERK responses after 5-minute treatment with aLA (300 mM; black),
TUG-891 (10 mM; dark gray), or FBS (10%; light gray) are shown in untransfected cells (untreated), cells transfected with control nontargeting siRNA
(control), or cells transfected with b-arrestin-2 targeting siRNA (b-Arr-2). The inset shows RT-PCR results using b-arrestin-2 primers for reactions with
no template (NTC) or using RNA isolated from control or b-arrestin-2 siRNA transfected cells, performed either without or with reverse transcriptase
(RT) enzyme. (G) Fluorescent microscopy of either control or b-arrestin-2 siRNA transfected cells treated with vehicle or TUG-891 (10 mM; 45 minutes).
Scale bar = 100 mm. (H) High-content imaging results for TUG-891 (10 mM; 45 minutes) mediated internalization in control or b-arrestin-2 siRNA
transfected cells. ***P , 0.001.
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Fig. 3. FFA4 is rapidly internalized, phosphorylated, and desensitized after treatment with TUG-891. Internalization of an eYFP tagged form of hFFA4
was monitored by spinning disk confocal microscopy in live cells at 5-minute intervals after treatment with either (A) aLA (100 mM) or (B) TUG-891
(10 mM). (C) Quantitative assessment of the kinetics of internalization using a high-content imaging assay. (D) Concentration-response curves were
generated using each FFA4 agonist in the high-content internalization assay after a 45-minute ligand incubation. Phosphorylation of an hFFA4
construct containing an HA tag at the C terminus was assessed by [32P] incorporation, followed by immunoprecipitation for the HA tag. (E)
A representative [32P] autoradiograph (upper) and anti-HA immunoblot (lower) are shown, and polypeptides corresponding to the predicted size of
hFFA4-HA aremarked. (F) Quantification of the [32P] autoradiograph. (G) Tryptic phosphopeptidemaps. (H) A representative trace from single cell Ca2+
imaging desensitization experiments.
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generated from tryptically-digested hFFA4 were the same
when resolved by two-dimensional chromatography (Fig. 3G).
As an extension, we explored whether TUG-891 promoted
desensitization of the receptor-signaling response. Single-cell
Ca21 measurements allow repeated ligand treatment and
washout (Fig. 3H). Treatment with TUG-891 (3 mM) for 2
minutes resulted in a rapid increase in intracellular Ca21,
which returned to baseline after the ligand was removed.
A second 2-minute treatment with TUG-891 resulted in a
Ca21 response that was only 42% 6 12% of the original, and
a third treatment resulted in a further reduction to only 34%6
11% of the original response. This did not reflect a simple
rundown of capacity because when cells were stimulated
subsequently with ATP they were still competent to produce
a full Ca21 response.
FFA4 Rapidly Recycles Back to the Cell Surface and
Restores Responsiveness after Removal of TUG-891. We
next examined whether FFA4 can recycle and rapidly restore
responsiveness after washout of TUG-891. After inducing
expression in hFFA4 Flp-In T-REx 293 cells, doxycycline was
removed to cease de novo FFA4 production. Cells were then
treated with either vehicle (0.01% dimethylsulfoxide) or TUG-891
(10 mM) for 45 minutes, washed 4 times with HBSS containing
0.5% BSA to remove TUG-891, then either fixed immediately or
allowed to recover for 60 minutes and fixed before imaging by
fluorescence microscopy. Recovery of hFFA4-eYFP expression at
Fig. 4. FFA4 is rapidly recycled back to the cell surface and resensitized after removal of TUG-891. (A) Fluorescence microscopy images of hFFA4-eYFP
Flp-In T-REx 293 cells treated for 45minutes with dimethylsulfoxide (DMSO) vehicle (0.1%) or TUG-891 (10 mM), washed, then either fixed immediately
(0 minutes recovery) or allowed to recover for 60 minutes before fixing and imaging. Scale bar = 100 mm. Time course experiments were conducted in
these cells measuring (B) total FFA4-eYFP expression, (C) cell surface FFA4-eYFP expression (***P, 0.001 compared with vehicle treatment), and (D)
internalized FFA4-eYFP, in 10-minute intervals after first treating with DMSO vehicle (0.1%) or TUG-891 (10 mM) for 45 minutes. (E) Parallel
experiments where cells were treated with either DMSO vehicle (0.1%, black bars) or TUG-891 (10 mM, gray bars) for 45 minutes before washing and
then measuring the acute Ca2+ response to TUG-891 (10 mM) at 10-minute intervals. *P , 0.05; ***P , 0.001 compared with acute TUG-891 response
measured in vehicle desensitized cells at the same time point. Correlations are shown between (F) internalized receptor and cell surface expression, (G)
cell surface expression and Ca2+ response, and (H) internalized receptor and Ca2+ response. In G and H, fit lines were segmented at 50% cell surface
expression and 40% internalized receptor, respectively.
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the cell surface appeared to be largely complete within this time
period (Fig. 4A).
Such visual studies do not provide direct quantification. We
thus measured in parallel total hFFA4-eYFP expression
(measuring total eYFP), cell surface hFFA4-eYFP expression
(using cell surface ELISA against the N-terminal FLAG
epitope present in the hFFA4-eYFP construct), and internal-
ized FFA4-eYFP (employing high content imaging) in the
same samples after treatment with TUG-891 to stimulate
internalization. Cells were washed 4 times with HBSS con-
taining 0.5% BSA to remove the TUG-891, and fixed at
10-minute recovery intervals for up to 1 hour (Fig. 4, B–D).
There was no measurable receptor degradation, as the total
receptor-eYFP levels remained constant (Fig. 4B). Cell
surface FFA4-eYFP expression recovered from a statistically
significant (P , 0.001) 75% 6 8% decrease induced by treat-
ment with TUG-891 in a time-dependent manner such that by
60 minutes surface expression had returned to 78% 6 10% of
the vehicle-treated control. To confirm that this increase in cell
surface expression resulted from internalized receptors being
trafficked back to the cell surface, the amount of internalized
receptor measured in the high-content imaging assay demon-
strated a parallel decrease in internal receptor with increasing
recovery times (Fig. 4D).
We also assessed whether signaling responses to TUG-891
recovered as a result. After treatment of hFFA4 Flp-In T-REx
293 cells with either vehicle or TUG-891 (10mM) for 45minutes
and washing, the Ca21 responses to TUG-891 were assessed at
10-minute intervals (Fig. 4E). Although desensitization resulted
in a complete loss of TUG-891 response, by 10- and 20-minute
recovery the cells had regained an acute response to TUG-891.
At these time points, the recovered response was submaximal
being only 61% 6 5% (P , 0.001) and 83% 6 4% (P , 0.05),
respectively, of controls. However, between 30- and 60-minutes
after removal of TUG-891, recovery of Ca21 response was fully
resensitized, showing no difference (P . 0.05) from the control
(Fig. 4E).
To compare in detail the relationship between cell surface
expression recovery, reduction in internalized receptor, and
resensitization of the Ca21 signaling response, we generated
correlation plots for each of these parameters (Fig. 4, F–H). As
expected, there was a negative linear correlation (–0.94; P ,
0.01) when comparing surface expression and internalized
receptor (Fig. 4F). Interestingly, although there was a linear
relationship between FFA4 surface expression and Ca21
response, this was only true up to 50% cell surface expression,
after which there was no further increase in Ca21 response
(Fig. 4G). Similarly, although there was a negative relation-
ship between the amount of internalized receptor and the
Ca21 response, this again was only linear between ∼50 and
100% internalized receptor, as further reduction in the level
of internalized receptor had little affect the Ca21 response.
Together, these findings indicate that only approximately
50% surface expression of hFFA4 is required to achieve the
maximal Ca21 signal in these cells and demonstrates a signif-
icant level of receptor reserve.
TUG-891 Is an Orthosteric FFA4 Agonist. Binding of
fatty acid ligands to FFA1–3, the three structurally related
members of the FFA receptor family, has been shown to
involve ionic interactions between the carboxylate of the fatty
acid ligand and conserved, positively charged arginine residues
near the extracellular end of transmembrane domains (TMDs)
V andVII (Tikhonova et al., 2007; Stoddart et al., 2008b). These
residues are not conserved in FFA4. However, there are two
arginine residues close to the extracellular face of FFA4, R99 in
TMDII and R178 in TMDIV; several recent modeling an/or
mutational studies have suggested that R99 in particular is
important for ligand binding to FFA4 (Suzuki et al., 2008; Sun
et al., 2010;Watson et al., 2012).Whenassessed in theb-arrestin-2
Fig. 5. TUG-891 is an orthosteric agonist of FFA4. Concentration-
response curves are shown for (A) aLA and (B) TUG-891 at wild-type,
R99Q, and R178Q mutants of hFFA4 measured using the b-arrestin-2
recruitment assay in transiently transfected HEK293T cells. (C) Quanti-
tative measures of cell surface and total receptor expression for each
mutant.
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BRET interaction assay, aLA was unable to activate an R99Q
mutant form of hFFA4, but the activity and potency of this
ligand was unaffected at an R178Q hFFA4 mutant (Fig. 5A).
TUG-891 displayed the same pattern, losing function at R99Q
hFFA4 but not at R178Q hFFA4 (Fig. 5B), suggesting that R99
is critical to the binding of both endogenous fatty acids and
TUG-891.
To define that the lack of function observed at R99Q hFFA4
did not simply reflect lack of expression of the mutant, we
measured the relative expression levels of the wild-type and
mutant hFFA4 constructs both at the cell surface by ELISA
using an antibody directed against the N-terminal FLAG
epitope tag present in the constructs and for total expression
assessed by eYFP fluorescence (Fig. 5C). These experiments
demonstrated that R99Q hFFA4 did show statistically signif-
icantly less (P, 0.001) cell surface (29%6 4% of wild-type) and
total (60% 6 1% of wild-type) expression, whereas R178Q
hFFA4 had similar total expression to wild-type and only
modestly reduced cell surface expression (75% 6 5% of wild-
type). Hence, although neither mutant was delivered to the cell
surface as efficiently as wild-type hFFA4, both are able to reach
the cell surface in some level, suggesting that the complete lack
of ligand function at R99Q hFFA4 is consistent with this
residue being involved directly in ligand binding and function.
TUG-891 Is a Selective Agonist for hFFA4. Despite
limited homology between the two LCFA receptors, identify-
ing ligands that are markedly selective for FFA4 over FFA1
has been challenging. Thus, we examined the selectivity of
TUG-891 at hFFA4 compared with hFFA1 using the b-arrestin-
2 recruitment assay (Fig. 6, A–D). TUG-891 was markedly
selective for hFFA4, being some 288-fold more potent at
hFFA4 (pEC505 7.2260.06) than hFFA1 (pEC505 4.7660.29).
By contrast the fatty acid agonist aLA lacked selectivity,
being only 3-fold more potent at hFFA4 (pEC505 5.116 0.05)
than at hFFA1 (pEC50 5 4.63 6 0.15). As anticipated from
previous work (Briscoe et al., 2006), GW9508 was selective for
FFA1 (19-fold; pEC50 of 6.036 0.03 and 7.326 0.20 at hFFA4
and hFFA1, respectively) although displaying good potency at
hFFA4; NCG21 displayed modest, 12-fold selectivity for
hFFA4 (pEC50 5 5.72 6 0.08) over hFFA1 (4.63 6 0.15).
To examine the two apparently most FFA4 selective com-
pounds, NCG21 and TUG-891, in alternate signaling pathways,
we also compared the potency of these compounds in Ca21
assays for both hFFA4 and hFFA1 (Fig. 6, E and F). In these
assays NCG21 again showed modest, 8-fold selectivity for
hFFA4 (pEC505 5.0460.10) over hFFA1 (pEC505 4.1360.13),
whereas TUG-891 was again substantially more selective for
FFA4 (52-fold; pEC50 values of 7.026 0.09 and 5.306 0.04 for
hFFA4 and hFFA1, respectively).
Taken together, these experiments indicate that TUG-891
is the most potent and selective agonist of hFFA4 currently
described and is thus likely to represent the most suitable
ligand to explore the function of FFA4 in native human
systems.
TUG-891 Produces Similar Signaling Responses in
HT-29 Cells That Express hFFA4 Endogenously. We
next assessed whether TUG-891 could be used to examine
hFFA4 function in human-derived cells that endogenously
express the receptor. Two different isoforms of FFA4 have
been described in humans, differing by a 16-amino-acid insertion
in the third intracellular loop (Watson et al., 2012). We
designed RT-PCR primers anticipated to yield differently
sized PCR products from the short and the long isoforms, and
we used these to assess FFA4 transcript expression in the
human HT-29 adenocarcinoma cell line. A single fragment,
corresponding to the short isoform, was identified (Fig. 7A),
Fig. 6. TUG-891 is selective for hFFA4 over hFFA1. Concentration-response curves for (A) aLA, (B) GW9508, (C) NCG21, and (D) TUG-891 in
b-arrestin-2 recruitment BRET assays conducted in transiently transfected HEK293T cells for hFFA4 (black lines) and hFFA1 (gray lines).
Concentration-response data are also shown for (E) NCG21 and (F) TUG-891 in Flp-In T-REx cells induced to express hFFA4 (black lines) or hFFA1
(gray lines) in Ca2+ mobilization assays.
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indicating that HT-29 cells express the short but not
long isoform of FFA4. Both aLA and TUG-891 produced
concentration-dependent increases in intracellular Ca21
(Fig. 7B) in these cells, with TUG-891 substantially more
potent than aLA (pEC50 values of 5.35 6 0.10 and 4.48 6 0.16,
respectively). However, the potency of each ligand was
substantially lower than in the Ca21 assays performed with
Flp-In T-REx 293 cells heterologously expressing hFFA4
(Table 1).
Similar experiments explored ERK phosphorylation in
response to aLA or TUG-891 in HT-29 cells (Fig. 7C).
Concentration-dependent responses were again obtained for
both aLA (pEC505 3.466 0.27) and TUG-891 (pEC505 5.136
0.12). As in the hFFA4 Flp-In T-REx 293 cells, the potencies
of these two ligands in the pERK assay were lower than in
the Ca21 assay, suggesting that despite the reduced overall
potency in these cells the pharmacology of aLA and TUG-891 is
similar in the two systems.
TUG-891 Is Also a Potent Agonist of mFFA4. We have
previously noted marked differences in ligand potency between
species orthologs of other members of the FFA family (Hudson
et al., 2012a,b, 2013a). We examined, therefore, the activity
and potency of TUG-891 and other ligands at the mouse
ortholog of FFA4 (mFFA4). In the b-arrestin-2 recruitment
assay (Fig. 8A) the rank-order of potency atmFFA4was similar
to that observed at hFFA4: with TUG-891 (pEC50 5 7.77 6
0.09) . GW9508 (pEC50 5 6.54 6 0.05) . NCG21 (pEC50 5
5.77 6 0.05) . aLA (pEC50 5 5.07 6 0.07). We next assessed
whether TUG-891 also displayed a similar degree of selectivity
for mFFA4 over mFFA1 in the b-arrestin-2 assay (Fig. 8B).
TUG-891 displayed greater potency atmFFA1 (pEC505 5.926
0.16) than observed at hFFA1 (Fig. 6; pEC50 5 4.76 6 0.29).
Despite this, TUG-891 still displayed a substantial 61-fold
selectivity for mFFA4 over mFFA1 in this assay.
As we had observed potency and selectivity differences for
TUG-891 at hFFA4 between different assays, we also exam-
ined the selectivity of TUG-891 for mFFA4 over mFFA1 in
Ca21mobilization assays (Fig. 8C). TUG-891was found to have
reduced potency at mFFA4 (pEC50 5 6.89 6 0.04). Moreover,
TUG-891 displayed somewhat greater potency at mFFA1
(pEC50 5 6.41 6 0.08). As a result, the selectivity of TUG-891
for mFFA4 over mFFA1 was reduced to only 3-fold in the Ca21
assay.
The relatively low selectivity for TUG-891 at the mouse
orthologs in ability to elevate Ca21 suggests that using this
compound in murine-derived cells that coexpress both FFA4
and FFA1 is likely to limit its use in defining specific functions
of each receptor. Despite the availability of a substantial
pharmacologic armarium of FFA1 ligands, including antago-
nists as well as agonists, there is little information available
on possible selectivity of these compounds at mFFA1 versus
mFFA4. Therefore, to identify ligands that would be useful
to employ in concert with TUG-891 to define mFFA1 versus
mFFA4 function, we assessed TUG-905, an FFA1 agonist
(Christiansen et al., 2012) that we had previously noted to
be particularly potent at mFFA1. In Ca21 assays employing
Flp-In T-REx cells, TUG-905 was indeed a potent agonist of
mFFA1 (pEC50 5 7.03 6 0.06) (Fig. 8D), but it produced little
response at mFFA4 at concentrations up to 100 mM. TUG-905
is thus at least 1000-fold selective for mFFA1 over mFFA4
andmay be used to define function of FFA1 in murine-derived
cells and tissues.
We also explored the ability of GW1100 (Briscoe et al.,
2006), a FFA1 antagonist that we had confirmed to have no
effect at either hFFA4 or mFFA4 (data not shown), to inhibit
signals in response to TUG-905, TUG-891, or aLA at mFFA1.
In Ca21mobilization assays, GW1100 inhibited the responses
to each ligand in a concentration-dependentmanner with 10 mM
GW1100 completely blocking each response (Fig. 8E).
Together, these findings indicate that combinations of
TUG-891, TUG-905, and GW1100 would allow definition of
the contributions of mFFA4 and mFFA1 in mouse cells and
tissues that coexpress the two FFA receptors.
TUG-891 Stimulates GLP-1 Secretion in Both STC-1
and GLUTag Mouse Enteroendocrine Cell Lines. It has
previously been suggested that fatty acids stimulate secretion
of GLP-1 from enteroendocrine cells through activation of
FFA4 (Hirasawa et al., 2005). We re-examined this question
by initially defining whether TUG-891 could stimulate GLP-1
secretion from two different, mouse-derived enteroendocrine
cell lines, STC-1 and GLUTag. Expression of both mFFA1
and mFFA4 was shown in each cell line by RT-PCR (Fig. 9A).
In STC-1 cells, a robust, statistically significant (P , 0.001)
increase in GLP-1 secretion was produced on addition of either
aLA (100 mM) or TUG-891 (30 mM) (Fig. 9B). By contrast, only
a small, statistically nonsignificant increase was observed in
Fig. 7. TUG-891 produces signaling responses in HT-29 cells. (A)
Expression of FFA4 and FFA1 mRNA was assessed by RT-PCR in the
HT-29 human adenocarcinoma cell line. Concentration-response data in
HT-29 cells are shown for (B) Ca2+ and (C) ERK phosphorylation assays.
720 Hudson et al.
 at A
SPET Journals on February 5, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
response to TUG-905 (10 mM). The FFA1 antagonist GW1100
(10 mM) was without effect on aLA-induced GLP-1 secretion;
although GW1100 significantly reduced the response to TUG-
891 (P , 0.01), it did so by only 26% (Fig. 9B). GW1100 also
blocked the apparent small increase in GLP-1 secretion produced
by TUG-905.
When similar experiments were performed using theGLUTag
cell line, highly similar patterns of GLP-1 responses were
observed (Fig. 9C). Again both aLA (100 mM; P , 0.001) and
TUG-891 (30 mM; P , 0.01) increased GLP-1 secretion, but
TUG-905 again produced a marginal response that did not
reach statistical significance. Coaddition of GW1100 again
failed to inhibit the aLA response; in this case, it also did not
produce a statistically significant reduction in the response to
TUG-891 (P . 0.05).
Taken together, the data from these murine enteroendocrine
cell lines indicate that TUG-891 robustly stimulates GLP-1
release, primarily through activation of FFA4. However,
a small component of the TUG-891 GLP-1 response does
appear to be mediated by FFA1.
TUG-891 Stimulates Glucose Uptake in Differenti-
ated 3T3-L1 Adipocytes and Inhibits TNF Secretion
from RAW264.7 Macrophages. FFA4 expression has been
reported previously elsewhere in adipocytes and the receptor
suggested to stimulate increased glucose uptake (Oh et al.,
2010). When using differentiated 3T3-L1 mouse adipocytes as
amodel, treatment with aLA (100mM) produced a statistically
significant (P, 0.01) 92%6 20% increase in [3H]deoxyglucose
uptake by these cells (Fig. 10A). Treatment with TUG-891
(10 mM) also produced a statistically significant increase (P,
0.05) of [3H]deoxyglucose uptake, but in this case only by
47% 6 18%. The responses to either aLA or TUG-891 were
modest in comparison with the 557% 6 164% increase
observed upon challenge with insulin (1 mM) (Fig. 10A).
Despite the increases in [3H]deoxyglucose uptake produced
in response to aLA and TUG-891 being modest in extent,
they were concentration dependent, with a pEC50 of 4.69 6
0.28 and 5.86 6 0.29, respectively (Fig. 10, B and C). Although
lower than the potency measures obtained in cells heterolo-
gously expressing mFFA4, these potency differences are
similar to those observed between HT-29 cells endogenously
expressing the hFFA4 receptor and assays employing heter-
ologously expressed hFFA4.
A further area of potential FFA4 function that has received
substantial interest is that the receptor may mediate the anti-
inflammatory properties of the n-3 fatty acid docosahexaenoic
acid (DHA) in macrophage-like cells (Oh et al., 2010). In
RAW264.7 cells, LPS treatment produced a robust increase in
TNF secretion that was statistically significantly inhibited by
aLA (29% 6 12%; P , 0.05), TUG-891 (30% 6 6%; P , 0.05),
and DHA (88% 6 4%), but not by TUG-905 (Fig. 10D). These
results indicate that the FFA4 agonist TUG-891 can produce
an anti-inflammatory effect in these cells, albeit with sub-
stantially lower efficacy than DHA. The inhibition of TNF
secretion in these cells by both aLA and TUG-891 was also
concentration dependent, with pIC50 values of 4.796 0.39 and
5.86 6 0.29, respectively (Fig. 10, E and F), which is very
similar to the potencies observed for each ligand in the 3T3-L1
glucose uptake experiments.
Discussion
In recent years, GPCRs of the FFA family have been
receiving increasing interest for their potential use as novel
Fig. 8. TUG-891 is a potent agonist of mFFA4 but shows only limited assay-dependent selectivity over mFFA1. (A) Concentration-response data are
shown for various FFA4 agonists in the b-arrestin-2 recruitment assay using HEK293T cells transiently transfected with mFFA4. (B and C)
Concentration-response data for TUG-891 at mFFA4 (black lines) and mFFA1 (gray lines) in b-arrestin-2 recruitment (transiently transfected
HEK293T cells) and Ca2+ mobilization (Flp-In T-REx 293 stable inducible cells) assays, respectively. (D) Concentration-response data for the FFA1
selective agonist TUG-905 for both mFFA4 (black lines) and mFFA1 (gray lines). (E) Inhibition experiments are shown using Flp-In T-REx 293 cells
expressing mFFA1 and fixed concentrations of TUG-905 (100 nM), TUG-891 (3 mM), or aLA (3 mM) with increasing concentrations of the FFA1
antagonist GW1100.
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therapeutic targets in the treatment of both metabolic and
inflammatory conditions (Holliday et al., 2011; Hudson et al.,
2011, 2013b). Although the focus to date has been largely on
FFA1, interest in FFA4 has also been steadily increasing as
a target for the treatment of obesity and type 2 diabetes.
In large part, this reflects recent knockout, knockdown, and
genetic studies consistent with this receptor playing an
important role in GLP-1 secretion, b-cell survival, glucose
uptake, and insulin sensitization as well as producing anti-
inflammatory effects (Hirasawa et al., 2005; Oh et al., 2010;
Ichimura et al., 2012; Taneera et al., 2012). Despite this
interest, further validation of FFA4 as a therapeutic target
has been slowed by a lack of available small molecule ligands
for this receptor. The recent discovery of TUG-891, described
as a potent and selective agonist for FFA4 (Shimpukade et al.,
2012), has begun to address this deficit. In our current work,
we have used this ligand to explore the pharmacology and
function of FFA4 in various cell models that either heterol-
ogously or endogenously express species orthologs of this
receptor. The results generated demonstrate potential but
also significant challenges that may complicate the develop-
ment of FFA4 as a therapeutic target.
Comparison of TUG-891 with other currently available
agonists of FFA4—including the endogenous fatty acid aLA,
the FFA1 selective agonist GW9508 (Briscoe et al., 2006), and
the only other previously described FFA4 synthetic agonist
with a degree of selectivity, NCG21 (Suzuki et al., 2008)—
clearly demonstrated TUG-891 to be the most potent and
selective compound for hFFA4. Importantly, the signaling
pathways and responses for TUG-891 at hFFA4 were observed
to be very similar to those of the fatty acid aLA, producing
similar response kinetics, bias plot profiles, and efficacies in
all end points examined. This is consistent with TUG-891
being largely equivalent in function to aLA and, in concert
with both aLA and TUG-891 lacking function at the R99Q
hFFA4 mutant, with TUG-891 being an orthosteric agonist.
Interestingly, bias plots comparing the function of FFA4
agonists at ERK phosphorylation, b-arrestin-2 recruitment,
and Ca21 mobilization assays indicate that this receptor
shows a natural bias away from the ERK pathway (Gregory
et al., 2010, 2012), an observation that is further supported by
the noted lower potency for aLA and TUG-891 in the pERK
assaywhen employing human-derivedHT-29 cells that endog-
enously express FFA4. Because of this natural bias, we
explored in more detail specific mechanisms allowing FFA4-
mediated ERK phosphorylation, and we demonstrated an
apparent biphasic pERK response that was dependent on both
Gq/11 (early and later responses) and EGF receptor trans-
activation (late response only). Although previous work has
suggested that FFA4mediates a slow EGF-receptor–dependent
pERK response in Caco-2 adenocarcinoma cells (Mobraten
et al., 2013), the rapid ERK response was not observed in
these cells, which suggests that FFA4 activates ERK through
different pathways in different cell types. It was also in-
teresting to note that in spite of the very strong interaction
between FFA4 and b-arrestin-2, the ERK response in our
current study did not involve b-arrestin-2 signaling. Finally,
although the rapid pERK response was reduced substantially
by inhibition of Gq/11 signaling, it was not fully blocked, which
suggests that FFA4 couples to an as-yet-unknown Gq/11/
b-arrestin-2–independent signaling pathway(s) in these cells.
Complicating interpretation of the pharmacology of FFA4 is
our observation that the measured potency of both TUG-891
and aLA was substantially lower in cells endogenously ex-
pressing the receptor compared with values observed using
heterologous expression systems. Such observations often
reflect variation in receptor reserve, but both the b-arrestin-2
BRET and internalization assays are expected conceptually
to predict the affinity of the compound—the responses are
anticipated to directly reflect receptor occupancy (Hudson
et al., 2011) and thuswould not be expected to show substantial
effects of receptor reserve. However, our observation that only
50% cell surface recovery was needed to regain a full efficacy
Ca21 response in the FFA4 Flp-In T-REx 293 cells does suggest
Fig. 9. TUG-891 and aLA stimulate GLP-1 release primarily through
activation of FFA4. (A) The expression of FFA1 and FFA4 mRNA was
assessed in both STC-1 and GLUTag enteroendocrine cell lines. (B and C)
The secretion of GLP-1 was assessed in (B) STC-1 and (C) GLUTag cells
treated with either vehicle (open bars), ligand: aLA (100 mM), TUG-891
(30 mM), or TUG-905 (10 mM) (black bars), or ligand and GW1100 (10 mM).
**P , 0.01; ***P , 0.001 compared with vehicle treatment. ‡‡P , 0.01
compared with ligand without GW1100 treatment.
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that a receptor reserve is present, at least when measuring
Ca21 in this cell line. Considering this, there is clearly a need to
develop assays that can directly measure the affinity of ligands
at FFA4. Although such assays have been challenging for re-
ceptors with very lipophilic ligands, several approaches have
now been reported to directly measure ligand affinity at FFA1
(Hara et al., 2009b; Bartoschek et al., 2010; Negoro et al., 2012)
and may be equally suitable for studies with FFA4.
Although our work demonstrates TUG-891 to be the best
available ligand for analysis of function at hFFA4, with
similar signaling properties to the endogenous ligand aLA, we
also observed several issues that may complicate develop-
ment of this or other FFA4 agonists as therapeutics. First,
although previous work has shown that activation of FFA4 by
fatty acids stimulates both rapid phosphorylation (Burns and
Moniri, 2010) and internalization (Hirasawa et al., 2005) of
the receptor, the decreased Ca21 responses we observed upon
repeated exposure to TUG-891 suggest that receptor de-
sensitization may present a significant challenge for FFA4.
While this may present a challenge to drug development at
FFA4, our observation that FFA4 does recycle back the cell
surface and resensitize quickly after the removal of TUG-891
is encouraging, and long-term agonism of this receptor may
still be therapeutically viable. Clearly, it will be important for
future work to explore how these factors may affect long-term
FFA4 agonist treatment in vivo.
A second significant issue raised by this study is that the
selectivity of ligands for FFA4 cannot be assumed to be
equivalent across species. Most notably, although TUG-891
was more potent at mFFA4 than hFFA4 in the b-arrestin-2
assay, the opposite was true when measuring Ca21 elevation.
Coupled to the observation that TUG-891 was more potent at
mFFA1 than hFFA1, particularly again in Ca21 assays, TUG-
891 is likely to be only marginally selective for mFFA4 over
mFFA1, at least for end points that reflect Gq/11-mediated
signaling. Further complicating the issue is the observation
that TUG-891 and other FFA4 agonists displayed lower
potency in cell systems endogenously expressing the receptor.
This suggests that the most effective means to pharmacolog-
ically define a contribution of mFFA4 in mice or in cells
derived from themwhere FFA1 is coexpressed will require the
use of combinations of TUG-891 alongside FFA1 antagonists.
Although the development and detailed characterization of
FFA4 antagonists may, in time, overcome this issue, we
demonstrated the clear benefit of incorporating FFA1 antag-
onist studies in showing that TUG-891–stimulated GLP-1
release from both the murine STC-1 and GLUTag enter-
oendocrine cell lines is mediated predominantly by FFA4.
However, the partial effect of the FFA1 antagonist GW1100
on the effects of TUG-891 does suggest a contribution from
FFA1 as well. This is perhaps not surprising given the limited
FFA4/FFA1 selectivity of TUG-891 at the mouse orthologs,
and that both receptors have been linked to fatty acid
stimulated GLP-1 release in the past (Hirasawa et al., 2005;
Edfalk et al., 2008; Luo et al., 2012). Indeed, our findings with
TUG-891 may suggest that FFA1 and FFA4 produce additive
effects on GLP-1 release, consistent with the concept that
a dual agonist for these two receptors may be therapeutically
useful. The idea of a dual FFA1/FFA4 agonist for the treatment
of type 2 diabetes is potentially very interesting, given the
variety of beneficial effects each receptor has been linked with
(Holliday et al., 2011). In particular, the fact that FFA1
agonism is well known to enhance glucose-stimulated insulin
secretion in b cells and that FFA4 agonism promotes survival of
Fig. 10. TUG-891 stimulates glucose uptake in 3T3-L1 adipocytes and inhibits TNF secretion from RAW264.7 macrophages. (A) [3H]Deoxyglucose
uptake was measured in differentiated 3T3-L1 adipocytes in response to single concentrations of aLA (100 mM), TUG-891 (10 mM), and insulin (1 mM).
*P , 0.05; *** P , 0.001. (B and C) Concentration-response data were generated for (B) aLA and (C) TUG-891, with calculated EC50 values shown. (D)
The ability of aLA (100 mM), TUG-891 (10 mM), TUG-905 (10 mM), and DHA (100 mM) to inhibit LPS-stimulated TNF secretion from RAW264.7
macrophages. (E and F) Concentration-response data and the determined potency of (E) aLA and (F) TUG-891 to inhibit TNF secretion.
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these same cells makes a strong case for potentially synergistic
properties of dual FFA1/FFA4 agonists on insulin secretion and
b-cell maintenance. Moreover, given our observations with
TUG-891 at the mouse orthologs of these receptors, this
molecule may be an excellent candidate to test this hypothesis.
Although the poor selectivity of TUG-891 for FFA4 in mouse
systems presents challenges, this molecule can be extremely
useful for assessing FFA4 function in cells that do not express
FFA1. We took advantage of this to examine the properties
of TUG-891 in both differentiated 3T3-L1 adipocytes and
RAW264.7 macrophages, two cell lines previously shown to
express only FFA4 (Gotoh et al., 2007; Oh et al., 2010). TUG-
891 both stimulated insulin-independent glucose uptake in
3T3-L1 cells and inhibited LPS-induced TNF secretion from
RAW264.7 cells. These observations are consistent with
previous work indicating that n-3 fatty acids produce each of
these effects via activation of FFA4 (Oh et al., 2010). However,
it should also be noted that the magnitude of these TUG-891
responses was relatively small. For example, in glucose
uptake studies, TUG-891 produced a response that was only
8% of the maximal insulin response; inhibition of TNF
production by TUG-891, although of similar extent to that
produced by aLA, was only 34% of that observed with the
n-3 fatty acid DHA.
The fact that TUG-891 does not produce as large an effect
as DHA in regulation of inflammatory mediator release per-
haps indicates that the relatively high concentration of DHA
required results in at least some of its anti-inflammatory
effect being produced through mechanisms other than FFA4
activation, including previously described pathways involving
cyclooxygenase-2 or peroxisome proliferator-activated receptor
g (Li et al., 2005; Groeger et al., 2010). Together, the relatively
low efficacy of TUG-891 in both glucose uptake and anti-
inflammatory assays does raise questions as to whether this
or other FFA4 agonists will produce therapeutically relevant
responses and whether this may be related to our observa-
tions that FFA4 is rapidly phosphorylated, desensitized,
and internalized upon ligand activation.
Taken together, we have demonstrated that TUG-891 is a
potent and selective agonist for hFFA4 and that this compound
does produce many of the therapeutically beneficial effects
that have been attributed in the literature to FFA4 activation,
at least to some degree. However, we also note significantly
reduced selectivity of TUG-891 at mFFA4, which will make
using this compound in preclinical in vivo proof-of-principle
studies extremely challenging if the aim is to define specific
roles of mFFA4. Furthermore, the relatively low efficacy of
TUG-891 in several measured outputs raises questions as to
whether desensitization of this receptor may be an issue.
However, TUG-891 does produce a robust increase in GLP-1
secretion in the model systems employed, and this indicates
that if potential issues with ligand selectivity, response
efficacy, and desensitization can be overcome, FFA4 remains
an exciting possible target for the treatment of type 2 diabetes
and obesity.
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